Latest Conference Articles

February 25th 2012, 3:22pm

Oncology Nursing Society Congress

Meeting coverage from the 2012 Oncology Nursing Society Congress held at the New Orleans Ernest N. Morial Convention Center, from May 3-6, 2012.

February 24th 2012, 4:28pm

Hematologic Malignancies Congress

Dr. Kieron Dunleavy from the National Cancer Institute Discusses 3 Molecular Subtypes of DLBCL

February 24th 2012, 2:34pm

Hematologic Malignancies Congress

A number of studies suggest that there is a right and wrong way to proceed with initial therapy and transplant eligibility for patients with multiple myeloma.

February 24th 2012, 9:40am

Hematologic Malignancies Congress

Research has shown that DLBCL is heterogeneous, suggesting that patients with varying subtypes should receive different courses of treatment.

February 24th 2012, 9:39am

Hematologic Malignancies Congress

Dr. Stephen Ansell from the Mayo Clinic Describes Waldenström Macroglobulinemia

January 26th 2012, 3:23pm

Updates From the ICHG/ASHG 61st Annual Meeting

The treatment of Gaucher disease is poised to enter a new era as a result of advances in the understanding of the cellular pathways at work in the disorder.

January 21st 2012, 3:45pm

Updates From the ICHG/ASHG 61st Annual Meeting

Rogerio Vivaldi, MD, has vivid memories of the first patient with Gaucher disease ever treated in Brazil with enzyme replacement therapy.

January 18th 2012, 3:03pm

Updates From the ICHG/ASHG 61st Annual Meeting

The mood of the ICHG/ASHG 2011 congress often seemed buoyant as researchers discussed the doors that technology is helping to open.

January 14th 2012, 4:09pm

Updates From the ICHG/ASHG 61st Annual Meeting

Dr. Gregory Grabowski, from the University Cincinnati, Explains the Effects of Enzyme Therapy

January 11th 2012, 3:10pm

Updates From the ICHG/ASHG 61st Annual Meeting

Pramod K. Mistry, MD, PhD, from Yale University, discusses Gaucher disease

December 13th 2011, 4:27pm

ASH Annual Meeting and Exposition

Dr. Anthony Mato From the John Theurer Cancer Center Discusses the Benefits of the JTCC Retrospective Trial

December 13th 2011, 4:06pm

ASH Annual Meeting and Exposition

A collection of photos from the ASH 53rd annual meeting at the San Diego Convention Center in San Diego, CA, from December 10-13, 2011.

December 13th 2011, 3:12pm

ASH Annual Meeting and Exposition

PACE trial results show patients with previously treated CML achieved a 47% major cytogenetic response rate (MCyR) with ponatinib.

December 13th 2011, 10:07am

ASH Annual Meeting and Exposition

The phase III VISTA trial upholds a persistent and statistically significant survival benefit for bortezomib in previously untreated multiple myeloma patients.

December 12th 2011, 2:19pm

ASH Annual Meeting and Exposition

Treatment with GA101 (obinutuzumab) in patients with relapsed non-Hodgkin lymphoma (NHL) resulted in higher response rates compared with rituximab.

December 12th 2011, 2:15pm

ASH Annual Meeting and Exposition

Dr. Claudio Anasetti from the H. Lee Moffitt Cancer Center Discusses the Trade-offs of BMT and PBSC

December 12th 2011, 11:19am

ASH Annual Meeting and Exposition

First drug targeting Bruton's tyrosine kinase (Btk) produced high rates of remission in patients with CLL.

December 12th 2011, 10:22am

ASH Annual Meeting and Exposition

Twelve-year results from a Canadian Cancer Society Research Institute study shows chemotherapy alone increases survival in patients with Hodgkin Lymphoma.

December 12th 2011, 9:36am

ASH Annual Meeting and Exposition

Bone Marrow Transplant Survivor Study analysis suggests long-term survivors of HCT have high risk of chronic psychological, and physical health conditions

December 11th 2011, 1:37pm

ASH Annual Meeting and Exposition

Dr. Laurie Sehn from the British Columbia Cancer Agency Discusses the Efficacy of the CD20 Agent GA101